Oppenheimer raised the firm’s price target on Crinetics to $55 from $54 and keeps an Outperform rating on the shares. Paltusotine’s above-expectations results in acromegaly patients naive to, or washed off of, somatostatin receptor ligand treatment puts this once-daily oral on a clear path to late 2025 U.S. approval with a broad label, the firm notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRNX:
- 3 Best Stocks to Buy Now, 3/20/2024, According to Top Analysts
- Crinetics Pharmaceuticals’ Paltusotine Shows Promising Results
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Crinetics’ paltusotine in acromegaly meets all Phase 3 study endpoints
- Crinetics price target raised to $54 from $48 at Oppenheimer
